Literature DB >> 28847498

Imaging Features on Contrast-Enhanced Ultrasound and Clinical Characteristics of Hepatitis B Virus-Related Combined Hepatocellular-Cholangiocarcinoma: Comparison with Hepatitis B Virus-Related Hepatocellular Carcinoma.

Jieyi Ye1, Xiaoyan Xie1, Baoxian Liu1, Xiaoer Zhang1, Wei Wang1, Xiaowen Huang1, Mingde Lu1, Guangliang Huang2.   

Abstract

The objective of this study was to compare the clinical characteristics and imaging features on contrast-enhanced ultrasound (CEUS) of hepatitis B virus (HBV)-related combined hepatocellular-cholangiocarcinoma (CHC) and hepatocellular carcinoma (HCC). Thirty-one pathologically proven CHCs were included and 31 HCCs were randomly selected as controls. Elevated carbohydrate antigen (CA) 19-9 alone and simultaneous elevation of α-fetoprotein and CA19-9 were more frequent in CHC than in HCC patients (p = 0.004 and 0.029, respectively). On CEUS, homogeneous, heterogeneous and peripheral irregular rim-like enhancement was illustrated in 8 (25.8%), 12 (38.7%) and 11 (35.5%) CHCs and in 6 (19.4%), 23 (74.1%) and 2 (6.5%) HCCs, respectively (p = 0.007). Multivariate logistic regression analysis revealed CA19-9 elevation (p = 0.011, odds ratio [OR] = 6.545) and peripheral irregular rim-like enhancement on CEUS (p = 0.017, OR = 7.718) were independent variables. A receiver operating characteristic curve was plotted and the area under the curve was 0.740. CHC should be watched for in HBV-infected patients with liver tumor manifesting peripheral irregular rim-like enhancement on CEUS, accompanied by CA19-9 elevation.
Copyright © 2017 World Federation for Ultrasound in Medicine & Biology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Combined hepatocellular–cholangiocarcinoma; Contrast-enhanced ultrasound; Hepatitis B virus; Hepatocellular carcinoma

Mesh:

Substances:

Year:  2017        PMID: 28847498     DOI: 10.1016/j.ultrasmedbio.2017.07.016

Source DB:  PubMed          Journal:  Ultrasound Med Biol        ISSN: 0301-5629            Impact factor:   2.998


  6 in total

1.  The Predictive Value of Staging Systems and Inflammation Scores for Patients with Combined Hepatocellular Cholangiocarcinoma After Surgical Resection: a Retrospective Study.

Authors:  Chaobin He; Yize Mao; Jun Wang; Yunda Song; Xin Huang; Xiaojun Lin; Shengping Li
Journal:  J Gastrointest Surg       Date:  2018-04-17       Impact factor: 3.452

2.  CEUS and CT/MRI LI-RADS in Association With Serum Biomarkers for Differentiation of Combined Hepatocellular-Cholangiocarcinoma From Hepatocellular Carcinoma.

Authors:  Yan Zhou; Shanshan Yin; Lin Zhao; Xiang Zhang; Meng Li; Jianmin Ding; Kun Yan; Xiang Jing
Journal:  Front Oncol       Date:  2022-05-16       Impact factor: 5.738

3.  Diagnostic performance of LI-RADS version 2018 in differentiating hepatocellular carcinoma from other hepatic malignancies in patients with hepatitis B virus infection.

Authors:  Shuo Shao; Yingying Liang; Sichi Kuang; Jingbiao Chen; Qungang Shan; Hao Yang; Yao Zhang; Bin Wang; Kathryn J Fowler; Jin Wang; Claude B Sirlin
Journal:  Bosn J Basic Med Sci       Date:  2020-08-03       Impact factor: 3.363

4.  Contrast-enhanced ultrasound in association with serum biomarkers for differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and intrahepatic cholangiocarcinoma.

Authors:  Jie Yang; Ya-Han Zhang; Jia-Wu Li; Ying-Yu Shi; Jia-Yan Huang; Yan Luo; Ji-Bin Liu; Qiang Lu
Journal:  World J Gastroenterol       Date:  2020-12-14       Impact factor: 5.742

5.  Preoperative Differentiation of Combined Hepatocellular-Cholangiocarcinoma From Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: A Nomogram Based on Ultrasonographic Features and Clinical Indicators.

Authors:  Yanling Chen; Qing Lu; Weibin Zhang; Jiaying Cao; Yi Dong; Wenping Wang
Journal:  Front Oncol       Date:  2022-02-15       Impact factor: 6.244

6.  Ultrasound contrast agent Sonazoid for the diagnosis of hepatic epithelioid angiomyolipoma: a case report.

Authors:  Zhe Huang; Jun-Yi Xin; Kai-Yan Li
Journal:  BMC Gastroenterol       Date:  2021-12-20       Impact factor: 3.067

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.